Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Shrinidhi Nathany: Patients with CHIP May Be Predisposed to Higher Risk of Cytokine Release Syndrome after CAR-T
Shrinidhi Nathany/LinkedIn
Oct 26, 2025, 09:59

Shrinidhi Nathany: Patients with CHIP May Be Predisposed to Higher Risk of Cytokine Release Syndrome after CAR-T

Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial, shared a post on LinkedIn:

“New Research Alert!!!!!!!
CHIP Mutations May Amplify Inflammation in CAR-T Therapy

A fascinating new study (Zhang et al., J Transl Clin Transplant 2025) reveals that CRISPR knockdown of CHIP genes (DNMT3A, TET2, ASXL1) in macrophages drives increased production of inflammatory cytokines during CAR-T cell therapy including IL-6, MCP-1, and IL-1β.

Translation?
Patients with Clonal Hematopoiesis of Indeterminate Potential (CHIP) may be predisposed to higher risk of Cytokine Release Syndrome (CRS) after CAR-T.

This could reshape how we risk-stratify, monitor, and personalize CAR-T therapy especially in multiple myeloma and hematologic malignancies.”

Title: CRISPR knockdown of CHIP genes in macrophages drives increased production of inflammatory cytokines in CAR-T cell therapy

Authors: Chunyan Zhang, Scott R. Goldsmith, Myo Htut, June-Wha Rhee, Vibhuti Vyas, Mary C. Clark, Saro H. Armenian, Stephen J. Forman, Xiuli Wang

Shrinidhi Nathany: Patients with CHIP May Be Predisposed to Higher Risk of Cytokine Release Syndrome after CAR-T

Read the full article.

Stay updated with Hemostasis Today.

CHIP genes Chunyan Zhang CRISPR Health Hematology Hemostasis Today June-Wha Rhee Mary C. Clark Medicine Myo Htut Saro H. Armenian Scott R. Goldsmith Shrinidhi Nathany Stephen J. Forman Vibhuti Vyas Xiuli Wang
NewsFeed